We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) is scheduled to release third-quarter 2024 results on Nov. 8, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 3.03%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
Currently, the consensus estimate for revenues is pegged at $3.84 billion, indicating an improvement of 3.6% from the prior-year quarter’s reported figure. However, the consensus mark for earnings is pinned at 78 cents per share, implying a 14.7% year-over-year improvement.
Factors to Note
For the third quarter, Baxter expects sales to grow 3-4% on a reported basis and 4-5% at constant currency (cc). Adjusted earnings per share are expected to be between 77 cents and 79 cents.
Sustained demand and the positive impact of pricing are likely to have aided sales for the Medical Products and Therapies segment. Infusion Therapies and Technologies sales are likely to have benefited from the IV Solutions portfolio in the international market, as well as the solid performance of the infusion system portfolio. Moreover, recent FDA approvals for Novum IQ volume infusion pump and Dose IQ Safety Software might have accelerated growth for the segment. Moreover, the launch of Helion Integrated Surgical System in Thailand in July should have brought in additional revenues.
Sales in the Pharmaceutical segment are expected to have been boosted by strong growth in the U.S. injectables portfolio on the back of new launches as well as continued strong demand for services within the drug compounding portfolio internationally. The launch of five injectable products in the United States in April to provide ready-to-use formulations might have brought in additional revenues.
In May, Clinolipid received the FDA approval for an expanded indication to be used in pediatric patients, including preterm and term neonates. Softness in the primary care market is likely to have hurt Front line Care sales during the third quarter.
Renal Care segment sales reflected a recovering trend during the previous few quarters. The growth in sales during the second quarter was driven by positive pricing and demand for Acute Therapies and Peritoneal Dialysis products. This was partially offset by a decline in sales of in-center hemodialysis products due to select product and market exits. The trend is likely to have continued in the third quarter.
Sales in the Acute Therapies segment are also expected to have benefited from growth in the United States and strength in the APAC region.
The company is planning to complete the divestment of Renal Care and Acute Therapies segments during late 2024 or early 2025. It is currently in discussion with Carlyle Group for the divestment of its kidney care spinoff, Vantive, in a deal valued at more than $4 billion, including debt. BAX may provide an update on its progress during the third quarter earnings call.
Meanwhile, ongoing transformation initiatives are likely to have enhanced operational efficiencies, which might have led to lower expenses during the quarter. However, inflationary pressure, as well as freight and supply-chain constraints, are likely to have increased cost of goods, thereby hurting the gross margin. However, these headwinds are anticipated to have been softer than those in the previously reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Baxter this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for Baxter.
You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: Baxter currently has a Zacks Rank #3 (Hold).
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to come up with an earnings beat this reporting cycle.
The stock has risen 69.4% year to date. BWAY’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 139.68%.
Haemonetics (HAE - Free Report) has an Earnings ESP of +0.18% and a Zacks Rank of 2 at present.
The stock fell 12.3% year to date. HAE’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 3.46%.
ICU Medical (ICUI - Free Report) has an Earnings ESP of +2.67% and a Zacks Rank of 3 at present.
The stock has risen 73.8% year to date. ICUI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 32.06%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings
Baxter International Inc. (BAX - Free Report) is scheduled to release third-quarter 2024 results on Nov. 8, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 3.03%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Q3 Estimates
Currently, the consensus estimate for revenues is pegged at $3.84 billion, indicating an improvement of 3.6% from the prior-year quarter’s reported figure. However, the consensus mark for earnings is pinned at 78 cents per share, implying a 14.7% year-over-year improvement.
Factors to Note
For the third quarter, Baxter expects sales to grow 3-4% on a reported basis and 4-5% at constant currency (cc). Adjusted earnings per share are expected to be between 77 cents and 79 cents.
Sustained demand and the positive impact of pricing are likely to have aided sales for the Medical Products and Therapies segment. Infusion Therapies and Technologies sales are likely to have benefited from the IV Solutions portfolio in the international market, as well as the solid performance of the infusion system portfolio. Moreover, recent FDA approvals for Novum IQ volume infusion pump and Dose IQ Safety Software might have accelerated growth for the segment. Moreover, the launch of Helion Integrated Surgical System in Thailand in July should have brought in additional revenues.
Sales in the Pharmaceutical segment are expected to have been boosted by strong growth in the U.S. injectables portfolio on the back of new launches as well as continued strong demand for services within the drug compounding portfolio internationally. The launch of five injectable products in the United States in April to provide ready-to-use formulations might have brought in additional revenues.
In May, Clinolipid received the FDA approval for an expanded indication to be used in pediatric patients, including preterm and term neonates. Softness in the primary care market is likely to have hurt Front line Care sales during the third quarter.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote
Renal Care segment sales reflected a recovering trend during the previous few quarters. The growth in sales during the second quarter was driven by positive pricing and demand for Acute Therapies and Peritoneal Dialysis products. This was partially offset by a decline in sales of in-center hemodialysis products due to select product and market exits. The trend is likely to have continued in the third quarter.
Sales in the Acute Therapies segment are also expected to have benefited from growth in the United States and strength in the APAC region.
The company is planning to complete the divestment of Renal Care and Acute Therapies segments during late 2024 or early 2025. It is currently in discussion with Carlyle Group for the divestment of its kidney care spinoff, Vantive, in a deal valued at more than $4 billion, including debt. BAX may provide an update on its progress during the third quarter earnings call.
Meanwhile, ongoing transformation initiatives are likely to have enhanced operational efficiencies, which might have led to lower expenses during the quarter. However, inflationary pressure, as well as freight and supply-chain constraints, are likely to have increased cost of goods, thereby hurting the gross margin. However, these headwinds are anticipated to have been softer than those in the previously reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Baxter this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for Baxter.
You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: Baxter currently has a Zacks Rank #3 (Hold).
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to come up with an earnings beat this reporting cycle.
Brainsway (BWAY - Free Report) has an Earnings ESP of +100.00% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The stock has risen 69.4% year to date. BWAY’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 139.68%.
Haemonetics (HAE - Free Report) has an Earnings ESP of +0.18% and a Zacks Rank of 2 at present.
The stock fell 12.3% year to date. HAE’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 3.46%.
ICU Medical (ICUI - Free Report) has an Earnings ESP of +2.67% and a Zacks Rank of 3 at present.
The stock has risen 73.8% year to date. ICUI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 32.06%.